扩大靶向早期巨细胞病毒检测项目的分析
该研究回顾性分析了大型医疗系统(Intermountain Healthcare,IHC)实施的扩大靶向早期巨细胞病毒(CMV)检测项目。2021年3月1日至2022年8月31日期间,在39,245例活产中,有3450例(8.8%)接受了CMV检测,共诊断14例有症状的先天性CMV(cCMV)感染,患病率为每10万活产35.7例。作者认为该扩大靶向早期cCMV检测项目可能提高有症状cCMV病例的检出率,并建议将其视为普遍筛查或听力靶向早期CMV检测的可行替代方案。
要点
- 2021年3月1日至2022年8月31日期间,39,245例活产中3450例(8.8%)接受了CMV检测。
- cCMV检测最常见指征为小于胎龄儿(SGA)(68.2%),其次为巨头畸形(13.5%)、听力测试异常(5.0%)和小头畸形(4.4%)。
- 共诊断14例有症状cCMV感染,最常见的确诊指征为SGA(10例),患病率为每10万活产35.7例。
核心结论
- 扩大靶向早期cCMV检测项目可能提高有症状cCMV病例的检出率,应考虑作为普遍筛查或听力靶向早期CMV检测的可行替代方案。
研究设计与样本
- 回顾性综述,在三级医疗中心进行,对修改后的电子系统数据库进行回顾性分析,该系统在提供者开具CMV检测医嘱时纳入检测指征。
主要发现
- 2021年3月1日至2022年8月31日期间,IHC系统内39,245例活产中3450例(8.8%)接受了CMV检测。
- 自2019年正式实施该项目以来,年度CMV检测量增加近10倍:2021年完成2668例CMV检测,而2015年为289例。
- cCMV检测最常见指征为SGA(68.2%),其次为巨头畸形(13.5%)、听力测试异常(5.0%)和小头畸形(4.4%)。
- 共诊断14例cCMV感染婴儿,均符合有症状cCMV标准;导致阳性诊断的最常见指征为SGA(10例)。
- 阳性率对应的患病率为每10万活产35.7例有症状cCMV病例,与普遍cCMV筛查的预期数值相当。
临床怎么用
- 作者认为,扩大靶向早期cCMV检测项目可能提高有症状cCMV病例的检出率,应考虑作为普遍筛查或听力靶向早期CMV检测的可行替代方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Determine the detection rate from an expanded targeted early cytomegalovirus (CMV) testing program implemented from a large healthcare system (Intermountain Healthcare, IHC). STUDY DESIGN: Retrospective review. SETTING: Tertiary medical center. METHODS: An electronic system was modified to include indications for testing whenever a provider placed an order for CMV testing. A retrospective analysis of this database was performed. RESULTS: From March 1, 2021 to August 31, 2022, there were 3450 (8.8%) patients who underwent CMV testing out of 39,245 total live births within the IHC system. Since the formal implementation of this program in 2019, annual CMV testing has increased almost 10-fold: 2668 CMV tests were performed in 2021 compared to 289 CMV tests in 2015. The most frequent indication for congenital CMV (cCMV) testing was small for gestational age (SGA) (68.2%), followed by macrocephaly (13.5%), an abnormal hearing test (5.0%), and microcephaly (4.4%). Fourteen cCMV-infected infants were diagnosed all of them meeting the criteria for symptomatic cCMV. The most common indication resulting in a positive diagnosis was those who presented with SGA (n = 10 patients). The positivity rate would result in a prevalence of 35.7 symptomatic cCMV cases diagnosed per 100,000 live births, numbers comparable to those expected for universal cCMV screening. CONCLUSION: An expanded targeted early cCMV testing program may improve detection rates of symptomatic cCMV cases and should be considered as a feasible alternative approach to universal or hearing-targeted early CMV testing.
引用
- Suarez D, Nielson C, McVicar SB, et al. Analysis of an Expanded Targeted Early Cytomegalovirus Testing Program. Otolaryngol Head Neck Surg. 2023. PMID: 36884018. doi:10.1002/ohn.320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。